Pharmaceuticals for Inflammation and Cancer
Kancera is a world leader in developing small molecule drugs for cancer and inflammation.
Read MoreNew Class of Drug for Cancer and Inflammation
Kancera is a world leader in the clinical development of small-molecule drugs that block the Fractalkine system, which is a newly exploited cellular control system for the development of drugs against cancer and inflammation.
The company’s two main drug candidates are KAND567, currently in clinical phase II for treatment of acute inflammatory conditions, and KAND145, currently in clinical preparatory studies prior to the start of phase I against treatment-resistant ovarian cancer.
Statement from the CEO
Kancera has laid the foundation for new drugs against cancer and inflammation through medical discoveries, product development and clinical safety studies. Commercialization of the company's patent-pending assets takes place through partnerships with pharmaceutical companies following positive results from patient studies.
Thomas Olin, CEO Kancera AB
Read More Press Releases
-
2022-09-27Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
-
2022-09-22Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
-
2022-08-22Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
Events
-
Nov22022
Our team: innovation & experience
Our research and company development is done by employees with cutting-edge knowledge and long experience. Through our extensive network of contacts, we have created strong collaborations, which has enabled an extraordinary height of innovation.